Serial Number: 85683762

Word Mark: MABIMMUNE

Translation: The wording "MABIMMUNE" has no meaning in a foreign language.

Goods and Services: IC 001. US 001 005 006 010 026 046. G & S: Chemicals, namely, chemical preparations for biological assays, and medical kits/tests; industrial chemicals; chemical preparations for scientific purposes; chemical preparations for use in photography; biological materials, namely, biological tissue and cell cultures other than for medical or veterinary purposes, inoculants in the nature of biological microorganisms used for biomedical research; biological preparations, namely, biological tissue and cell cultures other than for medical or veterinary purposes, inoculants in the nature of biological microorganisms used for biomedical research; peptides for chemicals and foodstuff, namely, peptide substrates used in analyzing and detecting certain biomarkers for laboratory or research use; polypeptides, namely, peptide substrates used in analyzing and detecting certain biomarkers for laboratory or research use, protein antibodies, namely, monoclonal antibodies for in vitro or in-vivo scientific or research use, antibody reagents used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; Diagnostic preparations for scientific use

IC 003. US 001 004 006 050 051 052. G & S: Skin care preparations, namely, chemical peels for skin, anti-aging topical creams, anti-wrinkle topical creams, scar-reducing formulations, burn ointments, topical beauty products

IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations for keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema and chronic pulmonary disease, a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts. Metabolic diseases including diabetes mellitus; veterinary preparations for keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema and chronic pulmonary disease, a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts. Metabolic diseases including diabetes mellitus; tumor suppressing agents; preparations for treating neurodegenerative diseases; immunogenics, namely, pharmaceutical preparations for inducing immune responses for the treatment of oncology indications including lymphomas, sarcomas, carcinomas, leukemias, bacterial infections, parasitic disease; vaccines; antibodies, namely for treatment of anti-inflammatory, cardiovascular, oncological, and dematological indications; epitopes, namely, for the pre-clinical research and development of pharmaceutical preparations such as antibodies or active peptites, active epitopes in the form of a pharmaceutical preparation which modulate the biological activity of drug targets in-vivo; synthetic peptides for pharmaceutical purposes for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema and chronic pulmonary disease, cardiomyopathies a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts. Metabolic diseases including diabetes mellitus; sanitary preparations for medical purposes; biological preparations for medical purposes for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema and chronic pulmonary disease, cardiomyopathies a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts. Metabolic diseases including diabetes mellitus; biocides; Diagnostic preparations for medical or veterinary purposes; sanitary towels; dietetic food, namely, pasta, crackers, bread adapted for medical purposes; dietetic beverages, namely, tea, dietary beverages, protein shakes adapted for medical purposes; Algaecide chemicals for swimming pools; Biological tissue, bone, skin, blood vessels, cartilage, muscle, teeth, extracellular matrix, heart valves intended for subsequent implantation; Synthetic peptides and polypeptides for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema and chronic pulmonary disease, cardiomyopathies a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts. Metabolic diseases including diabetes mellitus

IC 041. US 100 101 107. G & S: Physical examination, namely, physical fitness training services, physical performance monitoring, ergometry

IC 042. US 100 101. G & S: Testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs; consultancy and providing information of testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs; testing, inspection or research of medical treatment and technique; research in the field of biotechnology and antibodies; providing information of testing, inspection or research of medical treatment and technique; scientific research of health care; testing, inspection or research of biology; computer software design, computer programming, or maintenance of computer software; computer hardware design and development; computer software design and development; consultancy and providing information in the field of development of pharmaceutical preparations

IC 044. US 100 101. G & S: Medical services; medical services in the field of immunity, cardiology, rheumatology, oncology, pneumology, neurology; providing medical information; physical examination, namely keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema and chronic pulmonary disease, cardiomyopathies a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts. Metabolic diseases including diabetes mellitus); preparation and dispensing of medications; dietary and nutritional guidance; consultancy and providing information of health care; veterinary services; beauty salons; animal sanitary; animal grooming; health care; consultancy and providing information in the fields of pharmaceuticals, biomedical research, medical imaging, diagnostics, human physiology and pathophysiology

Mark Drawing Code: (4) STANDARD CHARACTER MARK

Filing Date: 07/22/2012

Current Basis: 1B;44E

Original Filing Basis: 1B;44E

Owner: (APPLICANT) Mabimmune Diagnostics AG aktiengesellschaft SWITZERLAND Wagistrasse 13 Schlieren SWITZERLAND 8952

Attorney of Record: Janice Housey

Type of Mark: TRADEMARK. SERVICE MARK

Register: PRINCIPAL

Live/Dead Indicator: LIVE

SiteNo: 9421